Stem Cell Clinic

cryo cell | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health – Video

cryo cell | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health
http://www.cordbloodrecommendation.com They were first used to regenerate healthy blood and immune cells for cancer patients. The treatment that has to be provided for leukemia should be such, that it would increase the amount of White Blood cells in the blood stream. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. This procedure can likewise diagnose disorders like malformations of fetus, fetal infection such as toxoplasmosis or rubella, fetal platelet count inside mum, fetal anaemia, and isoimmunisation to name a few. To make a long story short, the Adult Stem Cells did the trick. If the amount is less, the collected cord blood is used for scientific researches. Within an hour of receiving the stem cell treatment, she was able to turn her head and partially lift her arms. If there is any complication during delivery, the entire idea is abandoned. It is always wise to preserve this waste blood of the baby which is otherwise thrown away. The placenta and umbilical cord is often discarded along with the hospital #39;s medical waste. It is a simple and safe procedure for the mother and the baby, and is done by the doctor or the nurse. These cells have a unique capability of ""adjusting in any environment inside the body"". This is still new methodology but holds great promise for the future of regenerative therapies. This enables stem ...From:myc0kyViews:0 0ratingsTime:01:18More inScience Technology

Here is the original post:
cryo cell | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health - Video

Jerry discusses his stem cell treatment for his arthritic shoulder by Dr Harry Adelson – Video

Jerry discusses his stem cell treatment for his arthritic shoulder by Dr Harry Adelson
Jerry discusses his stem cell treatment for his arthritic shoulder and torn rotator cuff by Dr Harry AdelsonFrom:Harry AdelsonViews:0 0ratingsTime:00:41More inScience Technology

See the original post here:
Jerry discusses his stem cell treatment for his arthritic shoulder by Dr Harry Adelson - Video

Marty one year out from his stem cell treatment by Dr Harry Adelson – Video

Marty one year out from his stem cell treatment by Dr Harry Adelson
Marty discusses the outcome from his stem cell treatment for his arthritic hip one year laterFrom:Harry AdelsonViews:0 0ratingsTime:00:50More inScience Technology

See the rest here:
Marty one year out from his stem cell treatment by Dr Harry Adelson - Video

Biotech Bits – Pluristem's science by press release?

Pluristem Therapeutics is taking heat for its failure to disclose the death of a child treated on a compassionate use basis with its experimental placental stem cell treatment.

Paul Knoepfler, a stem cell scientist and prolific stemblogger, bluntly criticizes Pluristem for what a bioethicist he interviewed called "science-by-press-release" in touting the apparent benefit of the treatment as life-saving, but failing to follow up.

In its defense, Israel-based Pluristem said it didn't know that the child had died until later, because the doctor and family didn't tell the company. Its statement also said Pluristem maintains a culture of transparency. And indications were that the treatment had improved the child's physical condition.

The bioethicist, associate professor Leigh Turner of the University of Minnesota Center for Bioethics, told Knoepfler that wasn't a good excuse:

"Transparency is important, but it appears that the company is being transparent about dramatic improvements in health of individuals receiving Pluristems PLX Cells while failing to issue press release disclosing case of a child who died after undergoing this experimental intervention."

In other words, if you're going to mention something favorable to your product, it's only ethical to mention the unfavorable. Once Pluristem had given favorable coverage to this compassionate-use case, the publicly traded company had an obligation to monitor the child's progress and tell the public of any future developments. Even if Pluristem was legally in the right (because the death apparently was not caused by the stem cell treatment), ethically it was wrong.

Knoepfler concluded by urging biotech companies working on stem cell treatments to keep this lesson in mind, and to be scrupulous in searching for and disclosing adverse events:

"Part of what is so disappointing about this case to me is that the PLX therapy might have real promise as a drug, promise that has been at least temporarily clouded by actions by the company. I hope the case does indeed provide lessons to all interested parties including other biotech companies working on stem cell treatments."

View post:
Biotech Bits - Pluristem's science by press release?

International Stem Cell Corp Announces Third Quarter 2012 Financial Results

CARLSBAD, CA--(Marketwire - Nov 9, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company focused on therapeutic and research products, today announced financial results for the three months ended September 30, 2012.

Three Months Ended September 30, 2012

Revenue for the three months ended September 30, 2012 totaled $1.19 million compared to $0.84 million for the same period in 2011.Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 46% and 37%, respectively. LSC and LCT accounted for 44% and 56% of total revenue in the three months ended September 30, 2012 compared to 43% and 57%, respectively, for the same period of 2011.

Research and development (R&D) expenses were $0.90 million for the three months ended September 30, 2012, compared to $1.13 million for the same period in 2011. The decrease was due primarily to lower stock-based compensation expense, lower personnel-related spending and lower consulting expenses, partially offset by higher stem cell line research and testing expenses and higher laboratory expenses associated with our Parkinson's disease program.

The Company continues to invest in its sales and marketing infrastructure. Marketing expenses for the three months ended September 30, 2012 were $0.48 million, compared to $0.37 million for the same period in 2011. The increase was primarily driven by investments to promote and build awareness of the Lifeline Skin Care brand and branded products. General and administrative expenses were $1.57 million, down 26% compared to the same period in 2011, as a result of ongoing operational efficiency initiatives.

Cash and cash equivalents totaled $2.38 million at September 30, 2012 compared to $1.34 million as of December 31, 2011 due primarily to two financing transactions totaling approximately $7.03 million completed in the first three months of 2012.

"We have made excellent progress in our therapeutic development programs, being able to start our non-human primate study in our Parkinson's disease program earlier than anticipated, and we remain on track to publish the results in the first half of next year," stated Dr. Andrey Semechkin, ISCO's CEO and Co-Chairman. "In addition, our results for the third quarter reflect good progress by LSC and LCT both in terms of growing sales and implementing their strategies. Particularly pleasing is LSC's continued revenue growth as they aim to diversify their sales channels, and LCT's strong quarter on quarter performance. General and administrative expenses continued to decrease reflecting our increased focus on cost containment.Looking ahead to next year, we anticipate our R&D expenses to increase further as we expand our pharmacology and safety studies and our Parkinson's program moves closer to IND filing in early 2014."

Q3 2012 Highlights:

Conference Call and Webcast Details:

Date: Friday, November 9, 2012 Time: 11:00 a.m. Eastern Time

Visit link:
International Stem Cell Corp Announces Third Quarter 2012 Financial Results

Judi’s November 8, 2012 Update – Video

Judi #39;s November 8, 2012 Update
Adult Stem Cell Treatment Update for Multiple Sclerosis, November 8, 2012From:judilecoqViews:5 0ratingsTime:05:29More inPeople Blogs

See the original post:
Judi's November 8, 2012 Update - Video